• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

溶瘤病毒疗法:癌细胞视角

Oncolytic Virotherapy: The Cancer Cell Side.

作者信息

Ehrlich Marcelo, Bacharach Eran

机构信息

Shmunis School of Biomedicine and Cancer Research, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv 6997801, Israel.

出版信息

Cancers (Basel). 2021 Feb 24;13(5):939. doi: 10.3390/cancers13050939.

DOI:10.3390/cancers13050939
PMID:33668131
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7956656/
Abstract

Cell autonomous immunity genes mediate the multiple stages of anti-viral defenses, including recognition of invading pathogens, inhibition of viral replication, reprogramming of cellular metabolism, programmed-cell-death, paracrine induction of antiviral state, and activation of immunostimulatory inflammation. In tumor development and/or immunotherapy settings, selective pressure applied by the immune system results in tumor immunoediting, a reduction in the immunostimulatory potential of the cancer cell. This editing process comprises the reduced expression and/or function of cell autonomous immunity genes, allowing for immune-evasion of the tumor while concomitantly attenuating anti-viral defenses. Combined with the oncogene-enhanced anabolic nature of cancer-cell metabolism, this attenuation of antiviral defenses contributes to viral replication and to the selectivity of oncolytic viruses (OVs) towards malignant cells. Here, we review the manners by which oncogene-mediated transformation and tumor immunoediting combine to alter the intracellular milieu of tumor cells, for the benefit of OV replication. We also explore the functional connection between oncogenic signaling and epigenetic silencing, and the way by which restriction of such silencing results in immune activation. Together, the picture that emerges is one in which OVs and epigenetic modifiers are part of a growing therapeutic toolbox that employs activation of anti-tumor immunity for cancer therapy.

摘要

细胞自主免疫基因介导抗病毒防御的多个阶段,包括识别入侵病原体、抑制病毒复制、重编程细胞代谢、程序性细胞死亡、旁分泌诱导抗病毒状态以及激活免疫刺激炎症。在肿瘤发展和/或免疫治疗环境中,免疫系统施加的选择压力导致肿瘤免疫编辑,即癌细胞免疫刺激潜力的降低。这种编辑过程包括细胞自主免疫基因表达和/或功能的降低,使得肿瘤能够逃避免疫,同时削弱抗病毒防御。结合癌细胞代谢中癌基因增强的合成代谢特性,抗病毒防御的这种减弱有助于病毒复制以及溶瘤病毒(OVs)对恶性细胞的选择性。在此,我们综述癌基因介导的转化和肿瘤免疫编辑如何结合起来改变肿瘤细胞的细胞内环境,以利于OV复制。我们还探讨致癌信号与表观遗传沉默之间的功能联系,以及限制这种沉默导致免疫激活的方式。综合来看,呈现出的图景是,OVs和表观遗传修饰剂是一个不断发展的治疗工具箱的一部分,该工具箱利用激活抗肿瘤免疫来进行癌症治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b808/7956656/7ed52f567de0/cancers-13-00939-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b808/7956656/7697bfe99701/cancers-13-00939-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b808/7956656/a508621c32df/cancers-13-00939-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b808/7956656/7ed52f567de0/cancers-13-00939-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b808/7956656/7697bfe99701/cancers-13-00939-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b808/7956656/a508621c32df/cancers-13-00939-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b808/7956656/7ed52f567de0/cancers-13-00939-g003.jpg

相似文献

1
Oncolytic Virotherapy: The Cancer Cell Side.溶瘤病毒疗法:癌细胞视角
Cancers (Basel). 2021 Feb 24;13(5):939. doi: 10.3390/cancers13050939.
2
Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade.使用组蛋白去乙酰化酶抑制剂和免疫检查点阻断克服溶瘤病毒疗法中的障碍。
Viruses. 2016 Jan 6;8(1):9. doi: 10.3390/v8010009.
3
Oncolytic viruses as immunotherapy: progress and remaining challenges.溶瘤病毒作为免疫疗法:进展与尚存的挑战
Onco Targets Ther. 2016 May 4;9:2627-37. doi: 10.2147/OTT.S63049. eCollection 2016.
4
Immune System, Friend or Foe of Oncolytic Virotherapy?免疫系统,溶瘤病毒疗法的朋友还是敌人?
Front Oncol. 2017 May 23;7:106. doi: 10.3389/fonc.2017.00106. eCollection 2017.
5
Antitumor Benefits of Antiviral Immunity: An Underappreciated Aspect of Oncolytic Virotherapies.抗病毒免疫的抗肿瘤益处:溶瘤病毒治疗的一个被低估的方面。
Trends Immunol. 2018 Mar;39(3):209-221. doi: 10.1016/j.it.2017.11.006. Epub 2017 Dec 20.
6
Fighting Cancer with Viruses: Oncolytic Virus Therapy in China.用病毒对抗癌症:中国的溶瘤病毒治疗。
Hum Gene Ther. 2018 Feb;29(2):151-159. doi: 10.1089/hum.2017.212.
7
Design and application of oncolytic viruses for cancer immunotherapy.溶瘤病毒在癌症免疫治疗中的设计与应用。
Curr Opin Biotechnol. 2020 Oct;65:25-36. doi: 10.1016/j.copbio.2019.11.016. Epub 2019 Dec 23.
8
Exploiting tumor epigenetics to improve oncolytic virotherapy.利用肿瘤表观遗传学提高溶瘤病毒治疗效果。
Front Genet. 2013 Sep 20;4:184. doi: 10.3389/fgene.2013.00184.
9
Recent advances in oncolytic virus-based cancer therapy.溶瘤病毒癌症治疗的最新进展。
Virus Res. 2019 Sep;270:197675. doi: 10.1016/j.virusres.2019.197675. Epub 2019 Jul 25.
10
NF-κB Signaling in Targeting Tumor Cells by Oncolytic Viruses-Therapeutic Perspectives.溶瘤病毒靶向肿瘤细胞中的NF-κB信号传导——治疗前景
Cancers (Basel). 2018 Nov 8;10(11):426. doi: 10.3390/cancers10110426.

引用本文的文献

1
cJun-N-terminal kinase activity and mitosis perturbation drive the 2-methoxyestradiol-mediated enhancement of viral oncolysis by Epizootic Hemorrhagic Disease Virus-Tel Aviv University.cJun氨基末端激酶活性和有丝分裂扰动驱动2-甲氧基雌二醇介导的流行性出血病病毒-特拉维夫大学对病毒溶瘤作用的增强。
Sci Rep. 2025 Jul 9;15(1):24624. doi: 10.1038/s41598-025-08687-8.
2
Cytokine-based immunotherapy for gastric cancer: targeting inflammation for tumor control.基于细胞因子的胃癌免疫疗法:靶向炎症以控制肿瘤
Explor Target Antitumor Ther. 2025 Apr 26;6:1002312. doi: 10.37349/etat.2025.1002312. eCollection 2025.
3
Current Landscape of Therapeutic Cancer Vaccines.

本文引用的文献

1
Regulation of PD-L1 Expression by NF-κB in Cancer.NF-κB 对肿瘤中 PD-L1 表达的调控。
Front Immunol. 2020 Nov 25;11:584626. doi: 10.3389/fimmu.2020.584626. eCollection 2020.
2
ATM inhibition enhances cancer immunotherapy by promoting mtDNA leakage and cGAS/STING activation.ATM 抑制通过促进 mtDNA 泄漏和 cGAS/STING 激活增强癌症免疫治疗。
J Clin Invest. 2021 Feb 1;131(3). doi: 10.1172/JCI139333.
3
Constitutive low expression of antiviral effectors sensitizes melanoma cells to a novel oncolytic virus.抗病毒效应物的组成性低表达使黑色素瘤细胞对新型溶瘤病毒敏感。
治疗性癌症疫苗的当前态势
Methods Mol Biol. 2025;2926:1-14. doi: 10.1007/978-1-0716-4542-0_1.
4
The Advances in the Development of Epigenetic Modifications Therapeutic Drugs Delivery Systems.表观遗传修饰治疗药物递送系统的研究进展。
Int J Nanomedicine. 2024 Oct 19;19:10623-10637. doi: 10.2147/IJN.S480095. eCollection 2024.
5
Alternative Strategies for Delivering Immunotherapeutics Targeting the PD-1/PD-L1 Immune Checkpoint in Cancer.递送靶向癌症中PD-1/PD-L1免疫检查点的免疫疗法的替代策略
Pharmaceutics. 2024 Sep 7;16(9):1181. doi: 10.3390/pharmaceutics16091181.
6
Arrest and Attack: Microtubule-Targeting Agents and Oncolytic Viruses Employ Complementary Mechanisms to Enhance Anti-Tumor Therapy Efficacy.抑制与攻击:微管靶向药物与溶瘤病毒利用互补机制增强抗肿瘤治疗效果。
Genes (Basel). 2024 Sep 11;15(9):1193. doi: 10.3390/genes15091193.
7
Sindbis Virus Vaccine Platform: A Promising Oncolytic Virus-Mediated Approach for Ovarian Cancer Treatment.辛德毕斯病毒疫苗平台:一种用于卵巢癌治疗的有前景的溶瘤病毒介导方法。
Int J Mol Sci. 2024 Mar 2;25(5):2925. doi: 10.3390/ijms25052925.
8
Channeling the Natural Properties of Sindbis Alphavirus for Targeted Tumor Therapy.利用辛德毕斯甲病毒的天然特性进行靶向肿瘤治疗。
Int J Mol Sci. 2023 Oct 6;24(19):14948. doi: 10.3390/ijms241914948.
9
Immunotherapy combining tumor and endothelium cell lysis with immune enforcement by recombinant MIP-3α Newcastle disease virus in a vessel-targeting liposome enhances antitumor immunity.免疫疗法结合肿瘤和内皮细胞溶解与免疫增强的重组 MIP-3α 新城疫病毒在血管靶向脂质体增强抗肿瘤免疫。
J Immunother Cancer. 2022 Mar;10(3). doi: 10.1136/jitc-2021-003950.
10
Single-cell RNA sequencing reveals a strong connection between upregulation and oncolytic HSV infection in tumor tissue.单细胞RNA测序揭示了肿瘤组织中上调与溶瘤性单纯疱疹病毒感染之间的紧密联系。
Mol Ther Oncolytics. 2021 Oct 20;23:330-341. doi: 10.1016/j.omto.2021.10.006. eCollection 2021 Dec 17.
Int J Cancer. 2021 May 1;148(9):2321-2334. doi: 10.1002/ijc.33401. Epub 2020 Dec 14.
4
The HUSH complex is a gatekeeper of type I interferon through epigenetic regulation of LINE-1s.HUSH 复合物通过 LINE-1s 的表观遗传调控成为 I 型干扰素的守门员。
Nat Commun. 2020 Nov 3;11(1):5387. doi: 10.1038/s41467-020-19170-5.
5
Functional genomic landscape of cancer-intrinsic evasion of killing by T cells.肿瘤细胞内在逃避 T 细胞杀伤的功能基因组景观
Nature. 2020 Oct;586(7827):120-126. doi: 10.1038/s41586-020-2746-2. Epub 2020 Sep 23.
6
Silencing and Transcriptional Regulation of Endogenous Retroviruses: An Overview.内源性逆转录病毒的沉默和转录调控:概述。
Viruses. 2020 Aug 13;12(8):884. doi: 10.3390/v12080884.
7
Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2.新型、强效二氢乳清酸脱氢酶(DHODH)抑制剂是广谱抗 RNA 病毒药物,可针对包括新型冠状病毒 SARS-CoV-2 在内的多种 RNA 病毒。
Protein Cell. 2020 Oct;11(10):723-739. doi: 10.1007/s13238-020-00768-w. Epub 2020 Aug 4.
8
Metabolic reprogramming as a feast for virus replication.代谢重编程:病毒复制的盛宴
Acta Virol. 2020;64(2):201-215. doi: 10.4149/av_2020_210.
9
SETDB1-Mediated Silencing of Retroelements.SETDB1 介导的逆转录元件沉默。
Viruses. 2020 May 30;12(6):596. doi: 10.3390/v12060596.
10
Targeting the innate immunoreceptor RIG-I overcomes melanoma-intrinsic resistance to T cell immunotherapy.靶向先天免疫受体 RIG-I 克服了黑色素瘤对 T 细胞免疫治疗的内在耐药性。
J Clin Invest. 2020 Aug 3;130(8):4266-4281. doi: 10.1172/JCI131572.